– Reuters
LianBio Announces First Patient Treated In Phase 1 Trial Of SHP2 Inhibitor BBP-398 In Combination With Osimertinib In Patients With Non-Small Cell Lung Cancer With EGFR Mutations
LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in its Phase 1 clinical
